Role of iron chelation therapy in thalassemia major

Turkish Journal of Haematology

Volumn 19, Issue 2, 2002, Pages 121-126

  Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; DEFERIPRONE; DEFEROXAMINE; DIHYDROXYPHENYL THIAZOLE; IRON CHELATING AGENT; POLYAZA DERIVATIVE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTHROPATHY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION PUMP; META ANALYSIS; NONHUMAN; REVIEW; THALASSEMIA MAJOR; URINARY EXCRETION;

EID: 0036399250     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Brit J Haematol 1998;101:399-406.
2. Hershko C, Hoffbrand AV. Iron chelation therapy. Reviews in Clinical and Experimental Hematology 2000;4:337-61.
3. Porter JB, Faherty A, Stallibrass L, Brookman L, Hassan L, Howes C. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Ann N Y Acad Sci 1998;850:485-7.
4. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000;95:2776-9.
5. Araujo A, Kosaryan M, MacDowell A, Wickens D, Puri S, Wonke B, Hoffbrand AV. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overkload. Brit J Haematol 1996;93:835-7.
6. Canatan D, Temimhan N, Dincer N, Ozsancak A, Oguz N, Temimhan M. Continuous desferrioxamine infusion by an infusor in thalassaemia major. Acta Paediatr 1999;88:550-2.
7. Brittenham GM, Farrell DE, Harris DE, Feldman ES, Danish EH, Muir DA, Tripp JH, Bellon EM. Magnetic susceptibility measurement of human iron stores. New Engl J Med 1982;307:1671-5.
8. Kreeftenberg HG Jr, Mooyaart EL, Huizenga JR, Sluiter WJ. Quantification of liver iron concentration with magnetic resonance imaging by combining T1, T2-weighted spin echo sequences and a gradient echo sequence. Neth J Med 2000;6:133-7.
9. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Koren G, Olvieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000;13:179-84.
10. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 2000;95:2975-82.
11. Porter JB, Abeysingher L, Marshall L, Hides RC, Singh S. Kinetics of removal and reapperance of nontransferrin bound plasma ion with desferrioxamine therapy. Blood; 1996;88:705-13.
12. Chapman RWG, Hussain MAM, Gorman A, Laulicht M, Politis D, Flynn DM, Sherlock S, Hoffbrand AV. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta thalassemia. J Clin Path 1982;35:481-6.
13. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
14. WHO. Therapy of thalassaemia. Recommendations for transfusion treatment of beta-thalassaemia major. 1985:237-55.
15. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984;1:392.
16. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia Blood 2000;95:1229-36.
17. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel, S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 1981;98:99-107.
18. Hershko C, Grady RW, Link G. Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med 1984;103:337-46.
19. Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C. IRC11, a new synthetic chelator with selective interaction with catabolic red blood cell iron. Evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. Blood 1997;90:4180-7.
20. Hershko C, Konijn AM, Nick HP, Link G. ICL67-0A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and RE iron stores and in iron-loaded rat heart cells in culture. Blood 2001;97:1115-22.
21. Barman Balfour JA, Foster RH. Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases. Drugs 1999;58:553-78.
22. Olivieri NF. Long-term therapy with deferiprone. Acta Haematol 1996;95:37-48.
23. Al-Refaie FN, Hoffbrand AV. Oral iron-chelating therapy: The L1 experience. Clin Haematol 1994;7:941-64.
24. Kontoghiorghes J, Aldouri MA, Sheppard L & Hoffbrand AV. 1,2 Dimethyl-3-hydroxyprid-4-one an orally active chelator for treatment of iron overload. Lancet 1987:1294-5.
25. Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocyosis and thrombocytopaenia in a patient with Blackfan-Diamond anaemia during oral iron chelator trial (Letter). Lancet 1989;ii:457.
26. Bartlett AN, Hoffbrand AV & Kontoghiorghes GJ. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): Clinical trial observations. British Journal of Haematology 1990;76:301-4.
27. Al-Refaie FN, Wonke B, Hoffbrand AV et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one(L1) in thalassaemia major. Blood 1992;80:593-9.
28. Olivieri NF, Brittenham JM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McLelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
29. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Brit J Haemat 1990;76:550-3.
30. Agarwal MB, Gupte SS, Viswanathan C, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Brit J Haemat 1992;82:460-6.
31. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B. Results of long-term deferiprone (L1) therapy: A report of the International Study Group on Oral Iron Chelators. Brit J Haemat 1995;91:224-9.
32. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 1998;339:417-23.
33. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakathul N, Jackson BFA, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
34. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Brit J Haematol 1998;101:413-5.
35. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305-12.
36. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999;55:1-6.
37. Tahar A, Chamoun FM, Koussa S, Aad MA, Khoriaty AI, Neeman R, Mourad FH. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173-7.
38. Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P, Kavouklis M, Aessopos A, Sakellaropoulos N, Karagiorga M, Kalotychou V, Loukopoulos D. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone. Haematologica 2000;85:115-7.
39. Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: Its efficacy relative to that of desferal. 38th Annual Meeting, American Society of Hematology. Orlando, FL. Blood 1996;(Suppl 1):1230A.
40. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Brit J Haematol 1998;103:361-4.
41. Aydinok Y, Nisli G, Kavakli K. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major. Brit J Haematol 1999;106:252-3.
42. Grady RW, Berdoukas VA, Rachmilewitz EA, Giardina PJ. Iron chelation therapy: A better approach. The 7th International Conference on Thalassaemia and the Haemoglobinopathies. Bangkok, Thailand, 31 May-4 June 1999: 0018A.
43. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamin-chelatable iron (DCI), a component of serum nontransferrin iron (NTBI) used for assessing iron chelation therapy. Blood 2001;97:792-8.
44. Agarwal MB, Rajadhyaksha G, Sameer A. Deferiprone: How to make it work more widely, effectively and without adverse effect: An Indian study. The 7th International Conference on Thalassaemia and the Haemoglobinopathies. Bangkok, Thailand, 31 May-4 June 1999; 1304A.